Evan Ya-Wen Yu, MD
The prognosis for patients with castration-sensitive prostate cancer continues to improve, with the recent FDA approval of abiraterone acetate (Zytiga), an agent that has shown promising survival signals. Results from the LATITUDE and STAMPEDE trials have contributed to this dramatic shift, said Evan Ya-Wen Yu, MD.
Abiraterone was approved in February 2018 for use in combination with prednisone for patients with metastatic highrisk castration-sensitive prostate cancer. This approval was based on findings from the phase III LATITUDE trial, in which the addition of abiraterone and prednisone to androgen deprivation therapy (ADT) demonstrated a 38% reduction in the risk of death compared with ADT alone.1
The STAMPEDE trial also investigated abiraterone, showing that it lowered the relative risk of death by 37% when added to standard ADT. Additionally, abiraterone improved progressionfree survival by 71% in metastatic and nonmetastatic patients with high-risk hormone-nave prostate cancer.2
In an interview during the 2018 OncLive State of the Science Summit on Genitourinary Cancers, Yu, a professor in the Division of Oncology at the University of Washington, and member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discussed the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between ...